Cargando…
Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase()
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943556/ https://www.ncbi.nlm.nih.gov/pubmed/36822409 http://dx.doi.org/10.1016/j.jinf.2023.02.029 |
| _version_ | 1784891732247183360 |
|---|---|
| author | Wan, Eric Yuk Fai Wang, Boyuan Mathur, Sukriti Chan, Cheyenne I. Ying Yan, Vincent Ka Chun Lai, Francisco Tsz Tsun Chui, Celine Sze Ling Li, Xue Wong, Carlos King Ho Li, Philip Hei Lau, Chak Sing Wong, Ian Chi Kei Chan, Esther Wai Yin |
| author_facet | Wan, Eric Yuk Fai Wang, Boyuan Mathur, Sukriti Chan, Cheyenne I. Ying Yan, Vincent Ka Chun Lai, Francisco Tsz Tsun Chui, Celine Sze Ling Li, Xue Wong, Carlos King Ho Li, Philip Hei Lau, Chak Sing Wong, Ian Chi Kei Chan, Esther Wai Yin |
| author_sort | Wan, Eric Yuk Fai |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9943556 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | The British Infection Association. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99435562023-02-22 Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase() Wan, Eric Yuk Fai Wang, Boyuan Mathur, Sukriti Chan, Cheyenne I. Ying Yan, Vincent Ka Chun Lai, Francisco Tsz Tsun Chui, Celine Sze Ling Li, Xue Wong, Carlos King Ho Li, Philip Hei Lau, Chak Sing Wong, Ian Chi Kei Chan, Esther Wai Yin J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2023-06 2023-02-22 /pmc/articles/PMC9943556/ /pubmed/36822409 http://dx.doi.org/10.1016/j.jinf.2023.02.029 Text en © 2023 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Wan, Eric Yuk Fai Wang, Boyuan Mathur, Sukriti Chan, Cheyenne I. Ying Yan, Vincent Ka Chun Lai, Francisco Tsz Tsun Chui, Celine Sze Ling Li, Xue Wong, Carlos King Ho Li, Philip Hei Lau, Chak Sing Wong, Ian Chi Kei Chan, Esther Wai Yin Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase() |
| title | Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase() |
| title_full | Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase() |
| title_fullStr | Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase() |
| title_full_unstemmed | Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase() |
| title_short | Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase() |
| title_sort | molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute covid-19 phase() |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943556/ https://www.ncbi.nlm.nih.gov/pubmed/36822409 http://dx.doi.org/10.1016/j.jinf.2023.02.029 |
| work_keys_str_mv | AT wanericyukfai molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase AT wangboyuan molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase AT mathursukriti molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase AT chancheyenneiying molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase AT yanvincentkachun molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase AT laifranciscotsztsun molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase AT chuicelineszeling molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase AT lixue molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase AT wongcarloskingho molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase AT liphiliphei molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase AT lauchaksing molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase AT wongianchikei molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase AT chanestherwaiyin molnupiravirandnirmatrelvirritonavirreducemortalityriskduringpostacutecovid19phase |